

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently amended) A humanized monoclonal antibody that specifically binds to a Shiga toxin 1 (Stx1) or Shiga toxin 2 (Stx2) antigen-toxin-protein, comprising a constant region and a variable region, wherein said constant region comprises a human immunoglobulin constant region and said variable region ~~comprises~~ consists of the immunoglobulin heavy chain and light chain variable regions as shown in Figure 3 (SEQ ID NOs: 19 and 21) or the immunoglobulin heavy chain and light chain variable regions as shown in Figure 6 (SEQ ID NOs: 42 and 44), wherein the antibody specifically binds to Stx1 or Stx2 antigen.

2-16. (Cancelled)

17. (Previously presented) The humanized monoclonal antibody of claim 1, wherein said human immunoglobulin constant region is selected from the group consisting of IgG, IgA, and IgM.

18. (Previously presented) The humanized monoclonal antibody of claim 17,

wherein said human immunoglobulin constant region is IgG.

19. (Currently amended) A humanized monoclonal antibody which specifically binds to ~~Shiga toxin type 2 and Shiga toxin type 2~~ Stx2 antigen or Stx2 antigen variants, comprising a constant region and a variable region, wherein:

said constant region is a human immunoglobulin constant region, and

said variable region ~~comprises~~ consists of the murine 11E10 (ATCC Accession No. CRL ~~1987~~ 1907) variable region.

20-22. (Cancelled)

23. (Previously presented) A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier or diluent.

24-28. (Cancelled)

29. (Previously presented) A pharmaceutical composition comprising the antibody of claim 19 and a pharmaceutically acceptable carrier or diluent.

30-33. (Cancelled)

34. (Previously presented) The humanized monoclonal antibody of claim 19, wherein the human constant region is selected from the group consisting of IgG, IgA and IgM.

35. (Previously presented) The humanized monoclonal antibody of claim 34, wherein the human constant region is IgG.

36. (Previously presented) The humanized monoclonal antibody of claim 35, wherein the human constant region is IgG1-kappa.

37. (Currently amended) The humanized monoclonal antibody of claim 1, wherein the antibody specifically binds to Stx1 antigen and the variable region ~~comprises~~ consists of the amino acid sequence of SEQ ID NOs: 19 and 21.

38. (Currently amended) The humanized monoclonal antibody of claim 1, wherein the antibody specifically binds to Stx2 antigen and the variable region ~~comprises~~ consists of the amino acid sequence of SEQ ID NOs: 42 and 44.

39-43. (Cancelled)

44. (Currently amended) A pharmaceutical composition comprising a first and second antibody of claim 1 and a pharmaceutically acceptable carrier or diluent, wherein the first antibody of claim 1 specifically binds to Stx2 antigen and comprises a variable region consisting of the immunoglobulin heavy chain and light chain variable regions as set forth in SEQ ID NOs: 42 and 44 and the second antibody of claim 1 specifically binds to Stx1 antigen and comprises a variable region consisting of the immunoglobulin heavy chain and light chain variable regions as set forth in SEQ ID NOs: 19 and 21.

45-46. (Cancelled)

47. (Currently amended) The pharmaceutical composition of claim 29, further comprising a humanized monoclonal antibody that specifically binds to Stx1 antigen, wherein said humanized monoclonal antibody that specifically binds to Stx1 antigen comprises a variable region, wherein the variable region consists of the murine 13C4 (ATCC Accession No. CRL 1794) variable region, and a human immunoglobulin constant region.

48-53. (Cancelled)

54. (Currently amended) The pharmaceutical composition of claim 47, wherein said humanized antibody of claim 19 that specifically binds to Stx2 antigen or Stx2 antigen variants, comprises an IgG1 kappa human immunoglobulin constant region.

55. (Previously presented) The pharmaceutical composition of claim 47, wherein said humanized antibody that specifically binds to Stx1 antigen comprises an IgG1 kappa human immunoglobulin constant region.

56. (Currently amended) A humanized monoclonal antibody that specifically binds to ~~Shiga toxin type 1 and Shiga toxin type 1~~ Stx1 antigen or Stx1 antigen variants, comprising a constant region and a variable region, wherein:

said constant region is a human immunoglobulin constant region, and

said variable region ~~comprises~~ consists of the murine 13C4 (ATCC Accession No. CRL 1794) variable region.

57. (Previously presented) A pharmaceutical composition comprising the antibody of claim 56 and a pharmaceutically acceptable carrier or diluent.

58. (Previously presented) The humanized monoclonal antibody of claim 56, wherein the human constant region is selected from the group consisting of IgG, IgA and

IgM.

59. (Previously presented) The humanized monoclonal antibody of claim 58, wherein the human constant region is IgG.

60. (Previously presented) The humanized monoclonal antibody of claim 59, wherein the human constant region is IgG1-kappa.

61. (Currently amended) The pharmaceutical composition of claim 57, further comprising a humanized monoclonal antibody that specifically binds to Stx2 antigen, wherein said humanized monoclonal antibody that specifically binds to Stx2 antigen comprises a human immunoglobulin constant region and a variable region, wherein said variable region ~~comprises~~ consists of the murine 11E10 (ATCC Accession No. CRL 4987 1907) variable region.

62. (Currently amended) The pharmaceutical composition of claim 61, wherein said humanized monoclonal antibody that specifically binds to ~~Shiga toxin type 1 and~~ Shiga toxin type 1 Stx1 antigen or Stx1 antigen variants comprises an IgG1 kappa human immunoglobulin constant region.

63. (Previously presented) The pharmaceutical composition of claim 61, wherein said humanized antibody that specifically binds to Stx2 antigen comprises an IgG1 kappa human immunoglobulin constant region.